Your session is about to expire
← Back to Search
Radioimmunotherapy + Chemotherapy Before Stem Cell Transplant for Multiple Myeloma
Study Summary
This trial is testing a new cancer treatment that combines a targeted radioimmunotherapy drug with chemotherapy before a stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 87 Patients • NCT00075478Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any potential risks associated with Peripheral Blood Stem Cell Transplantation?
"There is a limited amount of evidence for the efficacy and safety of Peripheral Blood Stem Cell Transplantation, thus it was given a rating of 1."
What other research has taken place concerning Peripheral Blood Stem Cell Transplantation?
"At present, 32 trials are being conducted in relation to Peripheral Blood Stem Cell Transplantation. Of these active research programs, 3 are of Phase 3 status. Though the majority of such studies tare based out of Duarte California, there exist 886 sites hosting similar experiments across the US."
What is the scope of participants in this research study?
"Affirmative. According to clinicaltrials.gov, this study is actively looking for enrollees. It was first posted on December 1st 2022 and has since been updated as recenty as November 1st 2022. A total of 24 participants are needed at a single medical centre."
Are recruitments currently ongoing for this experiment?
"According to the clinicaltrials.gov information, this trial is actively searching for participants with its initiation dated December 1st 2022 and most recent update on November 1st 2022."
To what ailments is Peripheral Blood Stem Cell Transplantation typically administered?
"Peripheral Blood Stem Cell Transplantation is an efficacious treatment for malignant effusion, mycosis fungoides (mf), and chronic lymphocytic leukemia (CLL)."
Share this study with friends
Copy Link
Messenger